Ventrus BioSciences, Inc.
VTUS, today announced the online publication of the prior Phase 2b
study utilizing iferanserin, its novel investigational drug for the
treatment of symptomatic hemorrhoids, in the peer reviewed journal Clinical
Therapeutics. The article will appear in the February issue of Clinical
Therapeutics and is currently available online at the following link
http://www.sciencedirect.com/science/journal/aip/01492918. Data from this
trial have been previously disclosed by the company.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in